SER
Serina Therapeutics, Inc.
Price Chart
Latest Quote
$2.10
+0.12 (+6.06%)
Current Price
| Previous Close | $1.98 |
| Open | $1.99 |
| Day High | $2.15 |
| Day Low | $1.97 |
| Volume | 140,403 |
Stock Information
| Shares Outstanding | 15.00M |
| Total Debt | $3.34M |
| Cash Equivalents | $24.53M |
| Revenue | $130K |
| Net Income | $-21.52M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $31.49M |
| EPS (TTM) | $-2.00 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $15.25M |
| Sales | $130K |
| Income | $-21.52M |
| Book/sh | $0.85 |
| Cash/sh | $1.64 |
| Employees | 16 |
Financial Ratios
| Quick Ratio | 3.87 |
| Current Ratio | 4.18 |
| Debt/Eq | 18.93 |
Returns & Margins
| ROA | -89.79% |
| ROE | -221.93% |
| Operating Margin | -18803.08% |
Ownership
| Insider Ownership | 34.43% |
| Institutional Ownership | 9.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.00 |
| P/S | 242.27 |
| P/B | 2.46 |
Analyst Data
| Recommendation | none |
| Target Price | $11.00 |
Technical Indicators
| SMA20 | $1.88 |
| SMA50 | $1.85 |
| SMA200 | $2.99 |
| RSI | 65.12 |
| ATR | 0.1665 |
| Shares Float | 8.37M |
| Short Float | 3.00% |
| Short Ratio | 4.21 |
| Volatility | 0.10 |
| Rel Volume | 1.25 |
Performance History
| Week | +16.02% |
| Month | +30.43% |
| Quarter | -15.32% |
| 6 Months | -28.08% |
| YTD | +1.06% |
| Year | -64.04% |
| 3 Years | -91.16% |
| 5 Years | -96.16% |
| 10 Years | -97.83% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.10 | 187,700 |
| 2026-06-17 | $1.98 | 98,700 |
| 2026-06-16 | $2.04 | 141,700 |
| 2026-06-15 | $1.91 | 106,200 |
| 2026-06-12 | $1.84 | 161,900 |
| 2026-06-11 | $1.81 | 1,144,000 |
| 2026-06-10 | $1.74 | 55,100 |
| 2026-06-09 | $1.77 | 85,500 |
| 2026-06-08 | $1.90 | 60,600 |
| 2026-06-05 | $1.88 | 144,100 |
| 2026-06-04 | $1.86 | 147,000 |
| 2026-06-03 | $1.79 | 24,300 |
| 2026-06-02 | $1.76 | 20,600 |
| 2026-06-01 | $1.81 | 56,800 |
| 2026-05-29 | $1.84 | 55,300 |
| 2026-05-28 | $1.95 | 71,900 |
| 2026-05-27 | $1.80 | 44,200 |
| 2026-05-26 | $1.92 | 98,600 |
| 2026-05-22 | $1.98 | 198,100 |
| 2026-05-21 | $1.89 | 108,200 |
| 2026-05-20 | $1.70 | 116,000 |
| 2026-05-19 | $1.61 | 95,000 |
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
đ° Latest News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga âĸ 2026-05-13T12:06:16Z
Fed Politics Weigh on Investor Sentiment, Driving Muted Premarket Action for US Equity Futures
MT Newswires âĸ 2025-08-26T13:18:49ZExchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Investors Await Economic Data, Trump Orders to Remove Lisa Cook
MT Newswires âĸ 2025-08-26T12:46:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $3,000,000 | $500,000 |
| Operating Revenue | $0 | $0 | $3,000,000 | $500,000 |
| Expenses | ||||
| Interest Expense | $213,000 | $526,000 | $558,000 | $15,878 |
| Total Expenses | $24,022,000 | $17,048,000 | $6,129,000 | $2,770,368 |
| Other Income Expense | $5,038,000 | $6,367,000 | $8,956,000 | $-397,619 |
| Other Non Operating Income Expenses | $51,000 | $-6,789,000 | $7,879,000 | $-265,916 |
| Net Non Operating Interest Income Expense | $-213,000 | $-526,000 | $-558,000 | $-14,121 |
| Interest Expense Non Operating | $213,000 | $526,000 | $558,000 | $15,878 |
| Operating Expense | $24,022,000 | $17,048,000 | $6,129,000 | $2,770,368 |
| Other Operating Expenses | $-130,000 | $-56,000 | $-153,000 | $-91,500 |
| General And Administrative Expense | $10,997,000 | $9,624,000 | $3,894,000 | $1,288,783 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-19,182,000 | $-11,141,000 | $5,269,000 | $-2,682,108 |
| Net Interest Income | $-213,000 | $-526,000 | $-558,000 | $-14,121 |
| Normalized Income | $-23,121,730 | $-24,297,000 | $4,418,170 | $-2,550,405 |
| Net Income From Continuing And Discontinued Operation | $-19,182,000 | $-11,141,000 | $5,269,000 | $-2,682,108 |
| Total Operating Income As Reported | $-24,022,000 | $-17,048,000 | $-3,129,000 | $-2,270,368 |
| Net Income Common Stockholders | $-19,182,000 | $-11,141,000 | $5,269,000 | $-2,682,108 |
| Net Income | $-19,182,000 | $-11,141,000 | $5,269,000 | $-2,682,108 |
| Net Income Including Noncontrolling Interests | $-19,215,000 | $-11,207,000 | $5,269,000 | $-2,682,108 |
| Net Income Continuous Operations | $-19,215,000 | $-11,207,000 | $5,269,000 | $-2,682,108 |
| Pretax Income | $-19,197,000 | $-11,207,000 | $5,269,000 | $-2,682,108 |
| Operating Income | $-24,022,000 | $-17,048,000 | $-3,129,000 | $-2,270,368 |
| Average Dilution Earnings | - | $0 | $83,000 | - |
| Interest Income | - | - | - | $1,757 |
| Special Income Charges | - | - | - | $0 |
| Interest Income Non Operating | - | - | - | $1,757 |
| Per Share | ||||
| Diluted EPS | $-1.91 | $-1.51 | $0.63 | $-1.23 |
| Basic EPS | $-1.91 | $-1.51 | $0.63 | $-1.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $1,047,270 | $0 | $226,170 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-23,898,000 | $-23,643,000 | $4,840,000 | $-2,473,255 |
| Total Unusual Items | $4,987,000 | $13,156,000 | $1,077,000 | $-131,703 |
| Total Unusual Items Excluding Goodwill | $4,987,000 | $13,156,000 | $1,077,000 | $-131,703 |
| Reconciled Depreciation | $73,000 | $194,000 | $90,000 | $61,272 |
| EBITDA (Bullshit earnings) | $-18,911,000 | $-10,487,000 | $5,917,000 | $-2,604,958 |
| EBIT | $-18,984,000 | $-10,681,000 | $5,827,000 | $-2,666,230 |
| Diluted Average Shares | $10,190,000 | $7,359,000 | $8,413,889 | $7,548,000 |
| Basic Average Shares | $10,190,000 | $7,359,000 | $8,413,889 | $2,176,000 |
| Diluted NI Availto Com Stockholders | $-19,182,000 | $-11,141,000 | $5,352,000 | $-2,682,108 |
| Minority Interests | $33,000 | $66,000 | $0 | - |
| Tax Provision | $18,000 | - | - | - |
| Gain On Sale Of Security | $4,987,000 | $13,156,000 | $1,077,000 | $-131,703 |
| Research And Development | $13,155,000 | $7,480,000 | $2,388,000 | $1,573,085 |
| Selling General And Administration | $10,997,000 | $9,624,000 | $3,894,000 | $1,288,783 |
| Other Gand A | $10,997,000 | $9,624,000 | $3,894,000 | $1,288,783 |
| Gain On Sale Of Business | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-37,000 | $641,000 | $-32,294,000 | $-37,778,161 |
| Total Assets | $6,951,000 | $6,724,000 | $8,968,000 | $858,042 |
| Total Non Current Assets | $871,000 | $1,048,000 | $1,349,000 | $309,467 |
| Non Current Prepaid Assets | $29,000 | $0 | - | - |
| Current Assets | $6,080,000 | $5,676,000 | $7,619,000 | $548,575 |
| Other Current Assets | $309,000 | $77,000 | - | - |
| Prepaid Assets | $994,000 | $1,927,000 | - | $16,346 |
| Cash Cash Equivalents And Short Term Investments | $4,777,000 | $3,672,000 | $7,619,000 | $532,229 |
| Cash And Cash Equivalents | $3,056,000 | $3,672,000 | $7,619,000 | $532,229 |
| Receivables | - | - | - | $0 |
| Accounts Receivable | - | - | - | $0 |
| Cash Financial | - | - | - | $532,229 |
| Debt | ||||
| Total Debt | $3,142,000 | $268,000 | $3,445,000 | $1,808,655 |
| Long Term Debt And Capital Lease Obligation | $3,142,000 | $268,000 | $3,445,000 | $1,680,251 |
| Long Term Debt | $2,946,000 | - | $2,983,000 | $1,617,000 |
| Net Debt | - | - | - | $1,084,771 |
| Current Debt And Capital Lease Obligation | - | - | - | $128,404 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,988,000 | $6,216,000 | $41,262,000 | $38,636,203 |
| Total Non Current Liabilities Net Minority Interest | $3,425,000 | $3,850,000 | $39,849,000 | $38,198,517 |
| Derivative Product Liabilities | $283,000 | $3,582,000 | $0 | $1,076,766 |
| Current Liabilities | $3,563,000 | $2,366,000 | $1,413,000 | $437,686 |
| Other Current Liabilities | $425,000 | $193,000 | $250,000 | - |
| Payables And Accrued Expenses | $2,326,000 | $1,310,000 | $1,163,000 | $155,782 |
| Payables | $1,931,000 | $744,000 | $580,000 | $148,857 |
| Accounts Payable | $1,931,000 | $744,000 | $580,000 | $143,337 |
| Interest Payable | - | $0 | - | - |
| Current Deferred Liabilities | - | - | - | $153,500 |
| Other Payable | - | - | - | $5,520 |
| Equity | ||||
| Common Stock Equity | $-4,977,000 | $641,000 | $-32,294,000 | $-37,778,161 |
| Preferred Stock Equity | $4,940,000 | - | - | - |
| Total Equity Gross Minority Interest | $-37,000 | $508,000 | $-32,294,000 | $-37,778,161 |
| Stockholders Equity | $-37,000 | $641,000 | $-32,294,000 | $-37,778,161 |
| Gains Losses Not Affecting Retained Earnings | $-14,000 | $0 | - | - |
| Other Equity Adjustments | $-14,000 | - | - | - |
| Retained Earnings | $-63,500,000 | $-44,318,000 | $-33,177,000 | $-38,446,482 |
| Preferred Securities Outside Stock Equity | - | $0 | $36,404,000 | $35,441,500 |
| Other | ||||
| Ordinary Shares Number | $10,767,000 | $9,422,000 | $8,413,889 | $8,413,889 |
| Share Issued | $10,767,000 | $9,422,000 | $8,413,889 | $8,413,889 |
| Tangible Book Value | $-4,977,000 | $641,000 | $-32,294,000 | $-37,778,161 |
| Invested Capital | $-2,031,000 | $641,000 | $-29,311,000 | $-36,161,161 |
| Working Capital | $2,517,000 | $3,310,000 | $6,206,000 | $110,889 |
| Capital Lease Obligations | $196,000 | $268,000 | $462,000 | $191,655 |
| Total Capitalization | $2,909,000 | $641,000 | $-29,311,000 | $-36,161,161 |
| Minority Interest | $0 | $-133,000 | $0 | - |
| Additional Paid In Capital | $58,536,000 | $44,958,000 | $883,000 | $646,136 |
| Capital Stock | $4,941,000 | $1,000 | $0 | $22,185 |
| Common Stock | $1,000 | $1,000 | $0 | $22,185 |
| Preferred Stock | $4,940,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $196,000 | $268,000 | $462,000 | $63,251 |
| Pensionand Other Post Retirement Benefit Plans Current | $812,000 | $863,000 | - | - |
| Current Accrued Expenses | $395,000 | $566,000 | $583,000 | $6,925 |
| Net PPE | $842,000 | $1,048,000 | $1,349,000 | $309,467 |
| Accumulated Depreciation | $-528,000 | $-601,000 | $-390,000 | $-367,511 |
| Gross PPE | $1,370,000 | $1,649,000 | $1,739,000 | $676,978 |
| Other Properties | $1,258,000 | $1,513,000 | $1,613,000 | $571,241 |
| Machinery Furniture Equipment | $112,000 | $136,000 | $126,000 | $105,737 |
| Other Short Term Investments | $1,721,000 | $0 | - | $0 |
| Current Deferred Revenue | - | - | - | $153,500 |
| Current Capital Lease Obligation | - | - | - | $128,404 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-18,014,000 | $-17,159,000 | $-2,980,000 | $-2,085,306 |
| Operating Activities | ||||
| Operating Cash Flow | $-17,955,000 | $-17,137,000 | $-2,476,000 | $-2,075,624 |
| Cash Flow From Continuing Operating Activities | $-17,955,000 | $-17,137,000 | $-2,476,000 | $-2,075,624 |
| Operating Gains Losses | $-4,730,000 | $-13,156,000 | $-1,077,000 | $134,786 |
| Investing Activities | ||||
| Capital Expenditure | $-59,000 | $-22,000 | $-504,000 | $-9,682 |
| Investing Cash Flow | $-59,000 | $-22,000 | $-504,000 | $980,937 |
| Cash Flow From Continuing Investing Activities | $-59,000 | $-22,000 | $-504,000 | $980,937 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $12,484,000 | $5,000,000 | $0 | $4,422 |
| Financing Cash Flow | $17,412,000 | $13,212,000 | $10,067,000 | $1,312,070 |
| Cash Flow From Continuing Financing Activities | $17,412,000 | $13,212,000 | $10,067,000 | $1,312,070 |
| Net Preferred Stock Issuance | $4,940,000 | $0 | - | $0 |
| Preferred Stock Issuance | $4,940,000 | $0 | - | $0 |
| Net Common Stock Issuance | $7,544,000 | $5,000,000 | $0 | $4,422 |
| Common Stock Issuance | $7,544,000 | $5,000,000 | $0 | $4,422 |
| Net Other Financing Charges | - | $337,000 | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-168,000 | $-48,000 | $-3,692,352 |
| Issuance Of Debt | $4,913,000 | $3,043,000 | $10,100,000 | $5,000,000 |
| End Cash Position | $3,056,000 | $3,672,000 | $7,619,000 | $532,229 |
| Beginning Cash Position | $3,672,000 | $7,619,000 | $532,000 | $314,846 |
| Effect Of Exchange Rate Changes | $-14,000 | $0 | - | - |
| Changes In Cash | $-602,000 | $-3,947,000 | $7,087,000 | $217,383 |
| Proceeds From Stock Option Exercised | $15,000 | $5,000,000 | $15,000 | - |
| Net Issuance Payments Of Debt | $4,913,000 | $2,875,000 | $10,052,000 | $1,307,648 |
| Net Long Term Debt Issuance | $4,913,000 | $2,875,000 | $10,052,000 | $1,307,648 |
| Long Term Debt Payments | $0 | $-168,000 | $-48,000 | $-3,692,352 |
| Long Term Debt Issuance | $4,913,000 | $3,043,000 | $10,100,000 | $5,000,000 |
| Net PPE Purchase And Sale | $-59,000 | $-22,000 | $-504,000 | $-9,682 |
| Purchase Of PPE | $-59,000 | $-22,000 | $-504,000 | $-9,682 |
| Change In Working Capital | $1,470,000 | $-3,316,000 | $81,000 | $-11,939 |
| Change In Other Current Liabilities | $-169,000 | $-214,000 | $-188,000 | $-164,164 |
| Change In Payables And Accrued Expense | $966,000 | $-1,261,000 | $253,000 | $-3,891 |
| Change In Accrued Expense | $-231,000 | $400,000 | $-140,000 | $-2,973 |
| Change In Payable | $1,197,000 | $-1,661,000 | $393,000 | $-918 |
| Change In Account Payable | $1,197,000 | $-1,661,000 | $393,000 | $-2,131 |
| Change In Prepaid Assets | $673,000 | $-1,906,000 | $16,000 | $1,507 |
| Change In Receivables | $0 | $65,000 | $0 | $1,109 |
| Other Non Cash Items | $654,000 | $736,000 | $732,000 | $148,255 |
| Stock Based Compensation | $3,793,000 | $2,595,000 | $25,000 | $7,110 |
| Unrealized Gain Loss On Investment Securities | $0 | $7,017,000 | $-7,596,000 | $267,000 |
| Depreciation Amortization Depletion | $73,000 | $194,000 | $90,000 | $61,272 |
| Depreciation And Amortization | $73,000 | $194,000 | $90,000 | $61,272 |
| Gain Loss On Investment Securities | $-4,987,000 | $-13,156,000 | $-1,077,000 | $131,703 |
| Gain Loss On Sale Of PPE | $91,000 | $0 | - | $3,083 |
| Gain Loss On Sale Of Business | $166,000 | $0 | - | $0 |
| Net Income From Continuing Operations | $-19,215,000 | $-11,207,000 | $5,269,000 | $-2,682,108 |
| Interest Paid Supplemental Data | - | - | - | $15,878 |
| Net Investment Purchase And Sale | - | - | - | $990,619 |
| Sale Of Investment | - | - | - | $990,619 |
| Change In Other Working Capital | - | - | - | $153,500 |
| Changes In Account Receivables | - | - | - | $1,109 |
Fetched: 2026-06-20